PTC THERAPEUTICS INC (PTCT) Fundamental Analysis & Valuation

NASDAQ:PTCT • US69366J2006

Current stock price

65.72 USD
-0.41 (-0.62%)
Last:

This PTCT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. PTCT Profitability Analysis

1.1 Basic Checks

  • PTCT had positive earnings in the past year.
  • PTCT had a positive operating cash flow in the past year.
  • PTCT had negative earnings in 4 of the past 5 years.
  • PTCT had negative operating cash flow in 4 of the past 5 years.
PTCT Yearly Net Income VS EBIT VS OCF VS FCFPTCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M

1.2 Ratios

  • PTCT has a better Return On Assets (23.55%) than 97.10% of its industry peers.
  • The Return On Invested Capital of PTCT (35.09%) is better than 99.23% of its industry peers.
Industry RankSector Rank
ROA 23.55%
ROE N/A
ROIC 35.09%
ROA(3y)-10.27%
ROA(5y)-18.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTCT Yearly ROA, ROE, ROICPTCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

1.3 Margins

  • The Profit Margin of PTCT (39.44%) is better than 97.29% of its industry peers.
  • With an excellent Operating Margin value of 49.54%, PTCT belongs to the best of the industry, outperforming 99.61% of the companies in the same industry.
  • PTCT has a Gross Margin of 97.28%. This is amongst the best in the industry. PTCT outperforms 96.52% of its industry peers.
  • In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
Industry RankSector Rank
OM 49.54%
PM (TTM) 39.44%
GM 97.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.29%
GM growth 5Y0.47%
PTCT Yearly Profit, Operating, Gross MarginsPTCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PTCT Health Analysis

2.1 Basic Checks

  • PTCT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, PTCT has more shares outstanding
  • Compared to 5 years ago, PTCT has more shares outstanding
  • Compared to 1 year ago, PTCT has an improved debt to assets ratio.
PTCT Yearly Shares OutstandingPTCT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
PTCT Yearly Total Debt VS Total AssetsPTCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • PTCT has an Altman-Z score of 1.74. This is a bad value and indicates that PTCT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of PTCT (1.74) is better than 64.99% of its industry peers.
  • PTCT has a debt to FCF ratio of 3.70. This is a good value and a sign of high solvency as PTCT would need 3.70 years to pay back of all of its debts.
  • PTCT has a Debt to FCF ratio of 3.70. This is amongst the best in the industry. PTCT outperforms 92.07% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.7
Altman-Z 1.74
ROIC/WACC4.54
WACC7.72%
PTCT Yearly LT Debt VS Equity VS FCFPTCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B

2.3 Liquidity

  • PTCT has a Current Ratio of 2.35. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
  • PTCT has a Current ratio of 2.35. This is in the lower half of the industry: PTCT underperforms 72.34% of its industry peers.
  • PTCT has a Quick Ratio of 2.27. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of PTCT (2.27) is worse than 70.99% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.27
PTCT Yearly Current Assets VS Current LiabilitesPTCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PTCT Growth Analysis

3.1 Past

  • PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 228.79%, which is quite impressive.
  • PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 114.51%.
  • The Revenue has been growing by 35.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)228.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.33%
Revenue 1Y (TTM)114.51%
Revenue growth 3Y35.3%
Revenue growth 5Y35.36%
Sales Q2Q%0.01%

3.2 Future

  • The Earnings Per Share is expected to decrease by -7.93% on average over the next years.
  • PTCT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.89% yearly.
EPS Next Y-108.45%
EPS Next 2Y-57.41%
EPS Next 3Y-16.87%
EPS Next 5Y-7.93%
Revenue Next Year-45.22%
Revenue Next 2Y-19.16%
Revenue Next 3Y-6.87%
Revenue Next 5Y-1.89%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PTCT Yearly Revenue VS EstimatesPTCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
PTCT Yearly EPS VS EstimatesPTCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

5

4. PTCT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 8.49, which indicates a very decent valuation of PTCT.
  • Compared to the rest of the industry, the Price/Earnings ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 97.29% of the companies listed in the same industry.
  • PTCT is valuated cheaply when we compare the Price/Earnings ratio to 24.89, which is the current average of the S&P500 Index.
  • PTCT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 8.49
Fwd PE N/A
PTCT Price Earnings VS Forward Price EarningsPTCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • PTCT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PTCT is cheaper than 97.87% of the companies in the same industry.
  • 97.68% of the companies in the same industry are more expensive than PTCT, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.75
EV/EBITDA 5.77
PTCT Per share dataPTCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • A cheap valuation may be justified as PTCT's earnings are expected to decrease with -16.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-57.41%
EPS Next 3Y-16.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PTCT Dividend Analysis

5.1 Amount

  • No dividends for PTCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PTCT Fundamentals: All Metrics, Ratios and Statistics

PTC THERAPEUTICS INC

NASDAQ:PTCT (3/30/2026, 1:31:04 PM)

65.72

-0.41 (-0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)04-23
Inst Owners112.59%
Inst Owner Change3.84%
Ins Owners0.85%
Ins Owner Change9.83%
Market Cap5.44B
Revenue(TTM)1.73B
Net Income(TTM)682.64M
Analysts79.09
Price Target88.81 (35.13%)
Short Float %12.59%
Short Ratio7.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2175.84%
Min EPS beat(2)-4466.01%
Max EPS beat(2)114.33%
EPS beat(4)3
Avg EPS beat(4)103.66%
Min EPS beat(4)-4466.01%
Max EPS beat(4)4742.99%
EPS beat(8)5
Avg EPS beat(8)23.16%
EPS beat(12)5
Avg EPS beat(12)-13.42%
EPS beat(16)5
Avg EPS beat(16)-16.92%
Revenue beat(2)1
Avg Revenue beat(2)-6.39%
Min Revenue beat(2)-24.45%
Max Revenue beat(2)11.67%
Revenue beat(4)3
Avg Revenue beat(4)143.78%
Min Revenue beat(4)-24.45%
Max Revenue beat(4)585.33%
Revenue beat(8)5
Avg Revenue beat(8)74.62%
Revenue beat(12)7
Avg Revenue beat(12)49.28%
Revenue beat(16)9
Avg Revenue beat(16)36.95%
PT rev (1m)0.15%
PT rev (3m)6.53%
EPS NQ rev (1m)-2.97%
EPS NQ rev (3m)21.89%
EPS NY rev (1m)39.58%
EPS NY rev (3m)29.18%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)12.16%
Revenue NY rev (1m)4.83%
Revenue NY rev (3m)2.96%
Valuation
Industry RankSector Rank
PE 8.49
Fwd PE N/A
P/S 3.14
P/FCF 7.75
P/OCF 7.65
P/B N/A
P/tB N/A
EV/EBITDA 5.77
EPS(TTM)7.74
EY11.78%
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)8.49
FCFY12.91%
OCF(TTM)8.59
OCFY13.07%
SpS20.91
BVpS-2.48
TBVpS-8.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 23.55%
ROE N/A
ROCE 44.41%
ROIC 35.09%
ROICexc N/A
ROICexgc N/A
OM 49.54%
PM (TTM) 39.44%
GM 97.28%
FCFM 40.58%
ROA(3y)-10.27%
ROA(5y)-18.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.29%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.7
Debt/EBITDA 2.26
Cap/Depr 22.83%
Cap/Sales 0.51%
Interest Coverage 150.35
Cash Conversion 79.36%
Profit Quality 102.89%
Current Ratio 2.35
Quick Ratio 2.27
Altman-Z 1.74
F-Score7
WACC7.72%
ROIC/WACC4.54
Cap/Depr(3y)14.48%
Cap/Depr(5y)22.46%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)228.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.33%
EPS Next Y-108.45%
EPS Next 2Y-57.41%
EPS Next 3Y-16.87%
EPS Next 5Y-7.93%
Revenue 1Y (TTM)114.51%
Revenue growth 3Y35.3%
Revenue growth 5Y35.36%
Sales Q2Q%0.01%
Revenue Next Year-45.22%
Revenue Next 2Y-19.16%
Revenue Next 3Y-6.87%
Revenue Next 5Y-1.89%
EBIT growth 1Y702.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-84.2%
EBIT Next 3Y-24.99%
EBIT Next 5YN/A
FCF growth 1Y715.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y760.42%
OCF growth 3YN/A
OCF growth 5YN/A

PTC THERAPEUTICS INC / PTCT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PTC THERAPEUTICS INC (PTCT) stock?

ChartMill assigns a fundamental rating of 4 / 10 to PTCT.


What is the valuation status for PTCT stock?

ChartMill assigns a valuation rating of 5 / 10 to PTC THERAPEUTICS INC (PTCT). This can be considered as Fairly Valued.


Can you provide the profitability details for PTC THERAPEUTICS INC?

PTC THERAPEUTICS INC (PTCT) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for PTCT stock?

The Price/Earnings (PE) ratio for PTC THERAPEUTICS INC (PTCT) is 8.49 and the Price/Book (PB) ratio is -26.49.